GLP-1 News by Pen Hub

Wegovy 7.2 mg is on the horizon. Here’s what we know so far.

A daily tablet may soon join the GLP-1 lineup, giving people another option alongside injectables.

Despite its national launch, access to Mounjaro still depends heavily on where you live.

Pharmacies told to stop using “switch” or “stockpile” ads on slimming jabs as regulators clamp down after price hikes.

New study finds Wegovy outperforms Mounjaro for heart protection.

Several UK providers are giving patients short-term relief before the full hike hits.

Higher pharmacy costs expected from September, even with rebates in place.

Support may be needed for up to a year after stopping weight loss jabs, according to new expert guidance.

Real-world side effects of GLP-1 meds, as told on Facebook, now backed by science.

GLP-1s may do more than curb appetite; a new study suggests they could help ease asthma, too.

U.S. regulators just updated GLP-1 warnings, including Ozempic and Mounjaro. Here’s what they added.

Could a cheaper GLP-1 be just around the corner? Big pharma’s making moves, and the UK might feel the ripple.